Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler; Brad S Kahl; Peter Rosen; Jeffrey Matous; Amanda Cashen; Samuel Jacobs; Jeffrey Letzer; Bipinkumar Amin; Michael Williams; Maureen Ross; Sonali Smith; Alfred Saleh; Hongliang Shi; Sudha Parasuraman; Bruce D. Cheson

doi:10.1182/BLOOD.V114.22.933.933

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Nathan Fowler
, Brad S Kahl
, Peter Rosen
, Jeffrey Matous
, Amanda Cashen
, Samuel Jacobs
, Jeffrey Letzer
, Bipinkumar Amin
, Michael Williams
, Maureen Ross
, Sonali Smith
, Alfred Saleh
, Hongliang Shi
, Sudha Parasuraman
, Bruce D. Cheson

University of Texas MD Anderson Cancer Center
University of Wisconsin-Madison
Tower Cancer Research Foundation
Rocky Mountain Cancer Center, Denver, CO, USA,
Washington University in St. Louis
University of Pittsburgh
Kalamazoo Hematology/Oncology, Kalamazoo, MI, USA,
Mid Dakota Clinic, Bismarck, ND, USA,
University of Virginia
Cancer Outreach Associates, Abingdon, VA, USA,
University of Chicago
Sharp HealthCare
Millennium Pharmaceuticals
Georgetown University

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Blood
Volume	114
Issue number	22
DOIs	https://doi.org/10.1182/BLOOD.V114.22.933.933
State	Published - Nov 20 2009
Externally published	Yes

Disciplines

Immunology and Infectious Disease
Medicine and Health Sciences
Internal Medicine

Access to Document

10.1182/BLOOD.V114.22.933.933License: Unspecified

Cite this

Fowler, N., Kahl, B. S., Rosen, P., Matous, J., Cashen, A., Jacobs, S., Letzer, J., Amin, B., Williams, M., Ross, M., Smith, S., Saleh, A., Shi, H., Parasuraman, S., & Cheson, B. D. (2009). Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study. Blood, 114(22). https://doi.org/10.1182/BLOOD.V114.22.933.933

Fowler, N, Kahl, BS, Rosen, P, Matous, J, Cashen, A, Jacobs, S, Letzer, J, Amin, B, Williams, M, Ross, M, Smith, S, Saleh, A, Shi, H, Parasuraman, S & Cheson, BD 2009, 'Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.', Blood, vol. 114, no. 22. https://doi.org/10.1182/BLOOD.V114.22.933.933

@article{53ce658600ed445ba61087fd7a29c964,

title = "Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.",

author = "Nathan Fowler and Kahl, \{Brad S\} and Peter Rosen and Jeffrey Matous and Amanda Cashen and Samuel Jacobs and Jeffrey Letzer and Bipinkumar Amin and Michael Williams and Maureen Ross and Sonali Smith and Alfred Saleh and Hongliang Shi and Sudha Parasuraman and Cheson, \{Bruce D.\}",

note = "LYMPHOMA: THERAPY WITH BIOLOGIC AGENTS, EXCLUDING PRE-CLINICAL MODELS: TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-CD20 ANTIBODIES | Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D.",

year = "2009",

month = nov,

day = "20",

doi = "10.1182/BLOOD.V114.22.933.933",

language = "American English",

volume = "114",

journal = "Blood",

publisher = "American Society of Hematology",

number = "22",

}

TY - JOUR

T1 - Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

AU - Fowler, Nathan

AU - Kahl, Brad S

AU - Rosen, Peter

AU - Matous, Jeffrey

AU - Cashen, Amanda

AU - Jacobs, Samuel

AU - Letzer, Jeffrey

AU - Amin, Bipinkumar

AU - Williams, Michael

AU - Ross, Maureen

AU - Smith, Sonali

AU - Saleh, Alfred

AU - Shi, Hongliang

AU - Parasuraman, Sudha

AU - Cheson, Bruce D.

N1 - LYMPHOMA: THERAPY WITH BIOLOGIC AGENTS, EXCLUDING PRE-CLINICAL MODELS: TREATMENT OF B-CELL LYMPHOMAS WITH ANTI-CD20 ANTIBODIES | Nathan Fowler, Brad S Kahl, Peter Rosen, Jeffrey Matous, Amanda Cashen, Samuel Jacobs, Jeffrey Letzer, Bipinkumar Amin, Michael Williams, Maureen Ross, Sonali Smith, Alfred Saleh, Hongliang Shi, Sudha Parasuraman, Bruce D.

PY - 2009/11/20

Y1 - 2009/11/20

UR - https://ashpublications.org/blood/article/114/22/933/65051/Bortezomib-Bendamustine-and-Rituximab-in-Patients

U2 - 10.1182/BLOOD.V114.22.933.933

DO - 10.1182/BLOOD.V114.22.933.933

M3 - Article

VL - 114

JO - Blood

JF - Blood

IS - 22

ER -

Bortezomib, Bendamustine, and Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma: Encouraging Activity in the Phase 2 VERTICAL Study.

Disciplines

Access to Document

Other files and links

Cite this